CN102933199A - 含有烟碱的药物组合物 - Google Patents
含有烟碱的药物组合物 Download PDFInfo
- Publication number
- CN102933199A CN102933199A CN2011800285443A CN201180028544A CN102933199A CN 102933199 A CN102933199 A CN 102933199A CN 2011800285443 A CN2011800285443 A CN 2011800285443A CN 201180028544 A CN201180028544 A CN 201180028544A CN 102933199 A CN102933199 A CN 102933199A
- Authority
- CN
- China
- Prior art keywords
- nicotine
- levulinate
- pharmaceutical composition
- people
- patent number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 377
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 358
- 229960002715 nicotine Drugs 0.000 title claims abstract description 356
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 30
- 239000000203 mixture Substances 0.000 claims abstract description 193
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical group CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 claims abstract description 115
- 229940058352 levulinate Drugs 0.000 claims abstract description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
- 150000003839 salts Chemical group 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 17
- LDMPZNTVIGIREC-ZGPNLCEMSA-N nicotine bitartrate Chemical compound O.O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 LDMPZNTVIGIREC-ZGPNLCEMSA-N 0.000 claims abstract description 10
- 239000007937 lozenge Substances 0.000 claims description 75
- 229940112822 chewing gum Drugs 0.000 claims description 63
- 235000015218 chewing gum Nutrition 0.000 claims description 63
- 239000011347 resin Substances 0.000 claims description 35
- 229920005989 resin Polymers 0.000 claims description 35
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 30
- 239000011574 phosphorus Substances 0.000 claims description 30
- 229910052698 phosphorus Inorganic materials 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 20
- 239000007921 spray Substances 0.000 claims description 19
- 239000003513 alkali Substances 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 230000005586 smoking cessation Effects 0.000 claims description 5
- 230000002164 acetylcholinergic effect Effects 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical group 0.000 claims description 4
- 150000001447 alkali salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 2
- -1 sodium levulinate) Chemical class 0.000 abstract description 15
- 210000003169 central nervous system Anatomy 0.000 abstract description 7
- 150000002148 esters Chemical class 0.000 abstract description 5
- 238000002670 nicotine replacement therapy Methods 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 4
- GMEONFUTDYJSNV-UHFFFAOYSA-N Ethyl levulinate Chemical compound CCOC(=O)CCC(C)=O GMEONFUTDYJSNV-UHFFFAOYSA-N 0.000 abstract description 3
- 229940040102 levulinic acid Drugs 0.000 abstract 3
- UAGJVSRUFNSIHR-UHFFFAOYSA-N Methyl levulinate Chemical compound COC(=O)CCC(C)=O UAGJVSRUFNSIHR-UHFFFAOYSA-N 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 150000004730 levulinic acid derivatives Chemical class 0.000 abstract 1
- 229940069688 nicotine bitartrate Drugs 0.000 abstract 1
- 229960001698 nicotine polacrilex Drugs 0.000 abstract 1
- 229940058349 sodium levulinate Drugs 0.000 abstract 1
- RDKYCKDVIYTSAJ-UHFFFAOYSA-M sodium;4-oxopentanoate Chemical compound [Na+].CC(=O)CCC([O-])=O RDKYCKDVIYTSAJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 37
- 238000002360 preparation method Methods 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 25
- 238000002156 mixing Methods 0.000 description 23
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 14
- 230000008859 change Effects 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 210000000214 mouth Anatomy 0.000 description 13
- 230000001055 chewing effect Effects 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 235000015111 chews Nutrition 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 241000208125 Nicotiana Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000035807 sensation Effects 0.000 description 8
- 235000019615 sensations Nutrition 0.000 description 8
- 244000061176 Nicotiana tabacum Species 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 229940087730 nicorette Drugs 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229940095521 lozenge product Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- SNICXCGAKADSCV-SNVBAGLBSA-N (+)-nicotine Chemical compound CN1CCC[C@@H]1C1=CC=CN=C1 SNICXCGAKADSCV-SNVBAGLBSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000187656 Eucalyptus cornuta Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 229940078480 calcium levulinate Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- FFYVQVZXWDGRAY-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;hydrate Chemical compound O.CN1CCCC1C1=CC=CN=C1 FFYVQVZXWDGRAY-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- MQWJVKLIBZWVEL-XRIOVQLTSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.CN1CCC[C@H]1C1=CC=CN=C1 MQWJVKLIBZWVEL-XRIOVQLTSA-N 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- IGIDLTISMCAULB-UHFFFAOYSA-N 3-methylvaleric acid Chemical compound CCC(C)CC(O)=O IGIDLTISMCAULB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 240000005608 Ranunculus bulbosus Species 0.000 description 1
- 235000000903 Ranunculus bulbosus Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940095498 calcium polycarbophil Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940087496 habitrol Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical class O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 210000005172 vertebrate brain Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- BRTHFWPGJMGHIV-UHFFFAOYSA-L zinc;3-(1-methylpyrrolidin-2-yl)pyridine;dichloride;hydrate Chemical compound O.[Cl-].[Cl-].[Zn+2].CN1CCCC1C1=CC=CN=C1 BRTHFWPGJMGHIV-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/769,335 | 2010-04-28 | ||
| US12/769,335 US20110268809A1 (en) | 2010-04-28 | 2010-04-28 | Nicotine-Containing Pharmaceutical Compositions |
| PCT/US2011/033928 WO2011139684A2 (en) | 2010-04-28 | 2011-04-26 | Nicotine-containing pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102933199A true CN102933199A (zh) | 2013-02-13 |
Family
ID=44626142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800285443A Pending CN102933199A (zh) | 2010-04-28 | 2011-04-26 | 含有烟碱的药物组合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110268809A1 (https=) |
| EP (1) | EP2563330A2 (https=) |
| JP (1) | JP5981416B2 (https=) |
| CN (1) | CN102933199A (https=) |
| WO (1) | WO2011139684A2 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105263345A (zh) * | 2013-05-06 | 2016-01-20 | 派克斯实验公司 | 用于气溶胶装置的烟碱盐调配物及其方法 |
| CN108495563A (zh) * | 2015-11-25 | 2018-09-04 | R.J.雷诺兹烟草公司 | 烟碱盐、共晶体和盐共晶体配合物 |
| US11510433B2 (en) | 2013-12-05 | 2022-11-29 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| CA2824970C (en) | 2011-02-11 | 2016-05-03 | Batmark Limited | Inhaler component |
| SE535587C2 (sv) * | 2011-03-29 | 2012-10-02 | Chill Of Sweden Ab | Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse |
| WO2013006643A1 (en) * | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| US9474303B2 (en) | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
| US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
| US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
| US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
| US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| US20130177646A1 (en) * | 2012-01-05 | 2013-07-11 | Mcneil Ab | Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance |
| ES2759198T3 (es) * | 2012-02-06 | 2020-05-07 | Int Flavors & Fragrances Inc | Productos de administración por vía oral que incluyen objetos tridimensionales |
| US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
| US10517530B2 (en) | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
| US20140255452A1 (en) | 2013-03-11 | 2014-09-11 | Niconovum Usa, Inc. | Method and apparatus for differentiating oral pouch products |
| US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
| US10653180B2 (en) | 2013-06-14 | 2020-05-19 | Juul Labs, Inc. | Multiple heating elements with separate vaporizable materials in an electric vaporization device |
| US10357054B2 (en) | 2013-10-16 | 2019-07-23 | R.J. Reynolds Tobacco Company | Smokeless tobacco pastille |
| US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
| USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
| US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
| US9549573B2 (en) | 2013-12-23 | 2017-01-24 | Pax Labs, Inc. | Vaporization device systems and methods |
| USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
| KR102267997B1 (ko) | 2013-12-23 | 2021-06-23 | 쥴 랩스, 인크. | 기화 디바이스 시스템 및 방법 |
| US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
| US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
| WO2015175979A1 (en) | 2014-05-16 | 2015-11-19 | Pax Labs, Inc. | Systems and methods for aerosolizing a smokeable material |
| US20150335070A1 (en) | 2014-05-20 | 2015-11-26 | R.J. Reynolds Tobacco Company | Electrically-powered aerosol delivery system |
| EP3871515B1 (en) | 2014-05-27 | 2025-04-16 | R. J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| US11019840B2 (en) | 2014-07-02 | 2021-06-01 | R.J. Reynolds Tobacco Company | Oral pouch products |
| US10959456B2 (en) | 2014-09-12 | 2021-03-30 | R.J. Reynolds Tobacco Company | Nonwoven pouch comprising heat sealable binder fiber |
| WO2016099233A2 (ru) * | 2014-10-20 | 2016-06-23 | Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" | Фармацевтическая композиция для лечения туберкулеза |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| KR102627987B1 (ko) | 2014-12-05 | 2024-01-22 | 쥴 랩스, 인크. | 교정된 투여량 제어 |
| US20160157515A1 (en) | 2014-12-05 | 2016-06-09 | R.J. Reynolds Tobacco Company | Smokeless tobacco pouch |
| US9968125B2 (en) | 2015-01-09 | 2018-05-15 | Philip Morris Products S.A. | Nicotine—diketopiperazine microparticle formulations and methods of making the same |
| AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| US10154689B2 (en) | 2015-06-30 | 2018-12-18 | R.J. Reynolds Tobacco Company | Heat generation segment for an aerosol-generation system of a smoking article |
| US10149844B2 (en) | 2015-09-16 | 2018-12-11 | Philip Morris Products S.A. | Inhalable nicotine formulations, and methods of making and using thereof |
| US20170071248A1 (en) | 2015-09-16 | 2017-03-16 | Sansa Corporation (Barbados) Inc. | System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations |
| US9585835B1 (en) | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
| US11224594B2 (en) | 2015-09-16 | 2022-01-18 | Philip Morris Products S.A. | Nicotine formulations and methods of making and using the same |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| PL4292454T3 (pl) | 2015-11-24 | 2025-07-07 | Rai Strategic Holdings, Inc. | Zasilany elektrycznie system dostarczania aerozolu |
| US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
| CN117695207A (zh) * | 2015-12-24 | 2024-03-15 | 菲利普莫里斯生产公司 | 带香味尼古丁粉末 |
| WO2017117575A1 (en) * | 2015-12-30 | 2017-07-06 | Next Generation Labs, LLC | Nicotine replacement therapy products comprising synthetic nicotine |
| MX377347B (es) | 2016-02-11 | 2025-03-07 | Juul Labs Inc | Cartucho rellenable de vaporizador y metodo de relleno |
| WO2017139675A1 (en) | 2016-02-11 | 2017-08-17 | Pax Labs, Inc. | Securely attaching cartridges for vaporizer devices |
| CA3015306A1 (en) * | 2016-02-29 | 2017-09-08 | Nicogen Ltd. | Nicotine formulation and aerosols |
| US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
| US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
| USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
| USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
| USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
| US10602775B2 (en) | 2016-07-21 | 2020-03-31 | Rai Strategic Holdings, Inc. | Aerosol delivery device with a unitary reservoir and liquid transport element comprising a porous monolith and related method |
| US10617151B2 (en) | 2016-07-21 | 2020-04-14 | Rai Strategic Holdings, Inc. | Aerosol delivery device with a liquid transport element comprising a porous monolith and related method |
| US11660403B2 (en) | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
| US10080387B2 (en) | 2016-09-23 | 2018-09-25 | Rai Strategic Holdings, Inc. | Aerosol delivery device with replaceable wick and heater assembly |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| PL3614869T3 (pl) | 2017-04-24 | 2025-02-10 | Swedish Match North Europe Ab | Aromatyzowany wilgotny doustny produkt nikotynowy w saszetce zawierający trójgliceryd |
| EP4635478A3 (en) | 2017-09-05 | 2026-01-07 | R. J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
| US10786010B2 (en) | 2017-12-15 | 2020-09-29 | Rai Strategic Holdings, Inc. | Aerosol delivery device with multiple aerosol delivery pathways |
| US10555558B2 (en) | 2017-12-29 | 2020-02-11 | Rai Strategic Holdings, Inc. | Aerosol delivery device providing flavor control |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CN112384504A (zh) | 2018-06-15 | 2021-02-19 | R.J.雷诺兹烟草公司 | 烟碱的纯化 |
| US20200077703A1 (en) | 2018-09-11 | 2020-03-12 | Rai Strategic Holdings, Inc. | Wicking element for aerosol delivery device |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| US12342847B2 (en) | 2019-09-11 | 2025-07-01 | Nicoventures Trading Limited | Oral product with cellulosic flavor stabilizer |
| US12213510B2 (en) | 2019-09-11 | 2025-02-04 | Nicoventures Trading Limited | Pouched products with enhanced flavor stability |
| EP4072347B1 (en) | 2019-12-09 | 2025-02-12 | Nicoventures Trading Limited | Fleece for oral product with releasable component |
| EP4072338A1 (en) | 2019-12-09 | 2022-10-19 | Nicoventures Trading Limited | Agents for oral composition |
| US12171872B2 (en) | 2019-12-09 | 2024-12-24 | Nicoventures Trading Limited | Oral compositions and methods of manufacture |
| US12439949B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Oral compositions with reduced water activity |
| US12550928B2 (en) | 2019-12-09 | 2026-02-17 | Nicoventures Trading Limited | Liquid oral composition |
| US20210169138A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Fibrous fleece material |
| US11883527B2 (en) | 2019-12-09 | 2024-01-30 | Nicoventures Trading Limited | Oral composition and method of manufacture |
| US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
| US12137723B2 (en) | 2019-12-09 | 2024-11-12 | Nicoventures Trading Limited | Oral products with active ingredient combinations |
| US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
| US12491250B2 (en) | 2019-12-09 | 2025-12-09 | Nicoventures Trading Limited | Oral composition with nanocrystalline cellulose |
| CA3159451A1 (en) | 2019-12-09 | 2021-06-17 | Savannah JOHNSON | Pouched products with heat sealable binder |
| US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
| US12433321B2 (en) | 2019-12-09 | 2025-10-07 | Nicoventures Trading Limited | Oral composition with beet material |
| BR112022010981A2 (pt) | 2019-12-09 | 2022-08-23 | Nicoventures Trading Ltd | Produto oral em uma bolsa porosa compreendendo um material de velo |
| US12520867B2 (en) | 2019-12-09 | 2026-01-13 | Nicoventures Trading Limited | Buffered oral compositions |
| US12599160B2 (en) | 2019-12-09 | 2026-04-14 | Nicoventures Trading Limited | Lipid-containing oral composition |
| US11672862B2 (en) | 2019-12-09 | 2023-06-13 | Nicoventures Trading Limited | Oral products with reduced irritation |
| PH12022551272A1 (en) | 2019-12-09 | 2023-11-29 | Nicoventures Trading Ltd | Oral product with dissolvable component |
| US11889856B2 (en) | 2019-12-09 | 2024-02-06 | Nicoventures Trading Limited | Oral foam composition |
| US12439952B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Moist oral compositions |
| EP4072348A2 (en) | 2019-12-09 | 2022-10-19 | Nicoventures Trading Limited | Stimulus-responsive pouch |
| US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
| JP2023504756A (ja) | 2019-12-09 | 2023-02-06 | ニコベンチャーズ トレーディング リミテッド | カンナビノイドを含む口腔用製品 |
| US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
| US12151023B2 (en) | 2019-12-09 | 2024-11-26 | Nicoventures Trading Limited | Oral composition with beet material |
| US12310959B2 (en) | 2019-12-09 | 2025-05-27 | Nicoventures Trading Limited | Oral compositions with reduced water content |
| CA3181912A1 (en) | 2020-06-08 | 2021-12-16 | Anthony Richard Gerardi | Effervescent oral composition comprising an active ingredient |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103639A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
| US20220232881A1 (en) | 2021-01-28 | 2022-07-28 | Nicoventures Trading Limited | Method for sealing pouches |
| MX2023015529A (es) | 2021-06-25 | 2024-03-05 | Nicoventures Trading Ltd | Productos orales y metodo de fabricacion. |
| JP2024530905A (ja) | 2021-07-30 | 2024-08-27 | ニコベンチャーズ トレーディング リミテッド | 微結晶性セルロースを含むエアロゾル生成基材 |
| CA3131364A1 (en) * | 2021-09-20 | 2023-03-20 | Apotex Inc. | Novel salts of nintedanib and crystalline forms thereof |
| CA3233375A1 (en) | 2021-09-30 | 2023-04-06 | Michael Zawadzki | Oral product with a basic amine and an ion pairing agent |
| WO2023084499A1 (en) | 2021-11-15 | 2023-05-19 | Nicoventures Trading Limited | Products with enhanced sensory characteristics |
| CA3247270A1 (en) | 2022-04-06 | 2023-10-12 | Nicoventures Trading Limited | PRODUCTS IN BAGS WITH HEAT-SEALABLE BINDER |
| KR102848894B1 (ko) * | 2022-10-26 | 2025-08-21 | 한국원자력연구원 | 합성 니코틴의 감별 방법 |
| CN115997965A (zh) * | 2023-02-09 | 2023-04-25 | 东莞市吉纯生物技术有限公司 | 一种尼古丁缓释型口含烟及其制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1039530A (zh) * | 1987-02-10 | 1990-02-14 | R.J.雷诺兹烟草公司 | 香烟 |
| WO2006004646A1 (en) * | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
| CN1738621A (zh) * | 2002-12-20 | 2006-02-22 | 尼科诺瓦姆股份公司 | 物理和化学稳定的含尼古丁的颗粒物质 |
| US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
| CN101528199A (zh) * | 2006-03-16 | 2009-09-09 | 尼科诺瓦姆股份公司 | 改良的鼻烟组合物 |
| CN101563071A (zh) * | 2006-12-01 | 2009-10-21 | 赛福伦公司 | 尼古丁经口粘膜剂型 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2033909A (en) | 1934-12-19 | 1936-03-17 | Niacet Chemicals Corp | Manufacture of calcium levulinate |
| US3901248A (en) | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
| US3877468A (en) | 1970-07-22 | 1975-04-15 | Leo Ab | Chewable tobacco substitute composition |
| US3845217A (en) | 1972-11-16 | 1974-10-29 | Helsingborg L Ab | Buffered smoking substitute compositions |
| US4284809A (en) | 1979-04-02 | 1981-08-18 | The Upjohn Company | 13,14-Didehydro-inter-oxa-19-oxo-PGF1 compounds |
| GB8301659D0 (en) | 1983-01-21 | 1983-02-23 | Leo Ab | Smoking substitutes |
| US4655231A (en) | 1984-01-09 | 1987-04-07 | Advanced Tobacco Products, Inc. | Snuff and preparation thereof |
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4800903A (en) | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
| GB8615676D0 (en) | 1986-06-26 | 1986-07-30 | Stoppers Co Ltd | Nicotine containing lozenge |
| US4830028A (en) | 1987-02-10 | 1989-05-16 | R. J. Reynolds Tobacco Company | Salts provided from nicotine and organic acid as cigarette additives |
| IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| US5834011A (en) | 1988-02-19 | 1998-11-10 | The Regents Of The University Of California | Method for aiding in the reduction of incidence of tobacco smoking |
| US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| US5154927A (en) | 1989-01-19 | 1992-10-13 | Wm. Wrigley Jr. Company | Gum composition containing dispersed porous beads containing active chewing gum ingredients and method |
| US5525351A (en) | 1989-11-07 | 1996-06-11 | Dam; Anders | Nicotine containing stimulant unit |
| SE8904295D0 (sv) | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Smoking substitute |
| US5512306A (en) | 1992-06-19 | 1996-04-30 | Pharmica Ab | Smoking substitute |
| US5031646A (en) | 1990-01-16 | 1991-07-16 | R. J. Reynolds Tobacco Company | Cigarette |
| US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
| US5147654A (en) | 1990-07-23 | 1992-09-15 | Alza Corporation | Oral osmotic device for delivering nicotine |
| US5110605A (en) | 1990-08-21 | 1992-05-05 | Oramed, Inc. | Calcium polycarbophil-alginate controlled release composition and method |
| GB9200047D0 (en) | 1992-01-03 | 1992-02-26 | Univ Alberta | Nicotine-containing nasal spray |
| US6024097A (en) | 1992-02-20 | 2000-02-15 | J Mom Trust | Product for assisting a smoker in giving up the habit |
| US6098632A (en) | 1992-11-25 | 2000-08-08 | Pharmacia & Upjohn Ab | Nicotine-impermeable container and method of fabricating the same |
| US6602892B1 (en) | 1993-06-10 | 2003-08-05 | David P. L. Sachs | Methods for nicotine replacement dosage determination |
| WO1995001766A1 (en) | 1993-07-09 | 1995-01-19 | Cygnus Therapeutic Systems | Method and device for providing nicotine replacement therapy transdermally/transbuccally |
| US5549906A (en) | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US5362496A (en) | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| SE9303574D0 (sv) | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
| IT1274034B (it) | 1994-07-26 | 1997-07-14 | Applied Pharma Res | Composizioni farmaceutiche a base di gomma da masticare e procedimento per la loro preparazione |
| US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
| ES2217410T3 (es) | 1996-04-16 | 2004-11-01 | Novartis Consumer Health S.A. | Forma de dosificacion oral de rapida desintegracion. |
| US6166048A (en) | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
| GB9614902D0 (en) | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| US20030176467A1 (en) | 1997-09-25 | 2003-09-18 | Sven Andersson | Nicotine compositions |
| US6268386B1 (en) | 1998-06-25 | 2001-07-31 | Marshall Anlauf Thompson | Nicotine beverage |
| US6234169B1 (en) | 1998-08-14 | 2001-05-22 | Arthur Slutsky | Inhaler |
| US20020098264A1 (en) | 1998-11-27 | 2002-07-25 | Cherukuri Subraman R. | Medicated chewing gum delivery system for nicotine |
| US6358060B2 (en) | 1998-09-03 | 2002-03-19 | Jsr Llc | Two-stage transmucosal medicine delivery system for symptom relief |
| US6344222B1 (en) | 1998-09-03 | 2002-02-05 | Jsr Llc | Medicated chewing gum delivery system for nicotine |
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| SE9803986D0 (sv) | 1998-11-23 | 1998-11-23 | Pharmacia & Upjohn Ab | New compositions |
| GB9826192D0 (en) | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
| US7163705B2 (en) | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
| AU3470600A (en) | 1999-01-14 | 2000-08-01 | David Houze | Compositions and methods for drug delivery |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6090401A (en) | 1999-03-31 | 2000-07-18 | Mcneil-Ppc, Inc. | Stable foam composition |
| US6355265B1 (en) | 1999-04-06 | 2002-03-12 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
| US6322806B1 (en) | 1999-04-06 | 2001-11-27 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations including tableted center |
| US6426090B1 (en) | 1999-04-06 | 2002-07-30 | Wm. Wrigley Jr. Company | Over-coated product including tableted center and medicament |
| US6773716B2 (en) | 1999-04-06 | 2004-08-10 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
| US20010016593A1 (en) | 1999-04-14 | 2001-08-23 | Wilhelmsen Paul C. | Element giving rapid release of nicotine for transmucosal administration |
| US6248760B1 (en) | 1999-04-14 | 2001-06-19 | Paul C Wilhelmsen | Tablet giving rapid release of nicotine for transmucosal administration |
| US6583160B2 (en) | 1999-04-14 | 2003-06-24 | Steve Smith | Nicotine therapy method and oral carrier for assuaging tobacco-addiction |
| US6319510B1 (en) | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| GB9911037D0 (en) | 1999-05-13 | 1999-07-14 | Micap Limited | Nicotine delivery service |
| US20080138398A1 (en) | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
| US8256433B2 (en) | 1999-07-16 | 2012-09-04 | Aradigm Corporation | Systems and methods for effecting cessation of tobacco use |
| US6799576B2 (en) | 1999-07-16 | 2004-10-05 | Aradigm Corporation | System for effecting smoking cessation |
| US6322828B1 (en) | 1999-09-13 | 2001-11-27 | Deseret Laboratories, Inc. | Process for manufacturing a pharmaceutical chewing gum |
| US6660754B1 (en) | 2000-02-15 | 2003-12-09 | Smithkline Beecham Corporation | Method for reducing or eliminating smoking |
| US7115297B2 (en) | 2000-02-22 | 2006-10-03 | Suzanne Jaffe Stillman | Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| CA2359813C (en) | 2000-10-24 | 2008-04-22 | Richard L. Jones | Nicotine mucosal spray |
| SE0102197D0 (sv) | 2001-06-20 | 2001-06-20 | Pharmacia Ab | New product and use and manufacture thereof |
| US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| US7208186B2 (en) | 2001-09-18 | 2007-04-24 | Spi Pharma, Inc. | Chewing gum formulation and method of making the same |
| CA2468785A1 (en) | 2001-12-10 | 2003-06-19 | Joseph Robert Knight | Beverage treated with nicotine |
| SE0104388D0 (sv) | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| US20030159702A1 (en) | 2002-01-21 | 2003-08-28 | Lindell Katarina E.A. | Formulation and use manufacture thereof |
| WO2003066029A2 (en) | 2002-02-07 | 2003-08-14 | Pharmacia Corporation | Pharmaceutical dosage form for mucosal delivery |
| WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| US7105173B1 (en) | 2002-03-21 | 2006-09-12 | Rolling Kenneth J | Nicotine replacement applique |
| US20040101543A1 (en) | 2002-03-22 | 2004-05-27 | John Liu | Nicotine-containing oral dosage form |
| US7767698B2 (en) | 2002-06-03 | 2010-08-03 | Mcneil Ab | Formulation and use thereof |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US7135484B2 (en) | 2002-08-14 | 2006-11-14 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
| AU2002342577B2 (en) | 2002-09-24 | 2008-05-15 | Gumlink A/S | Low moisture chewing gum |
| EP1549153B1 (en) | 2002-09-24 | 2012-12-05 | Gumlink A/S | Chewing gum having improved release of chewing gum ingredients |
| EP1542542B2 (en) | 2002-09-24 | 2013-09-04 | Gumlink A/S | Biodegradable chewing gum comprising at least one high molecular weight biodegradable polymer |
| EP1549154A1 (en) | 2002-09-24 | 2005-07-06 | Gumlink A/S | Degradable chewing gum polymer |
| US6886557B2 (en) * | 2002-10-31 | 2005-05-03 | Hewlett-Packard Development Company, L.P. | Inhalation device and method for delivering variable amounts of different components |
| EP1449525A1 (en) | 2003-02-20 | 2004-08-25 | Cross Chem Llc | chewing gum in the form of multi-layer tablets |
| US20040182403A1 (en) | 2003-02-28 | 2004-09-23 | Sven-Borje Andersson | Container comprising nicotine and the use and manufacture thereof |
| CN100381083C (zh) | 2003-04-29 | 2008-04-16 | 韩力 | 一种非可燃性电子喷雾香烟 |
| BRPI0412752B8 (pt) | 2003-07-24 | 2021-05-25 | Glaxosmithkline Llc | composição de filme de dissolução oral |
| AU2004269986A1 (en) | 2003-09-08 | 2005-03-17 | Pfizer Consumer Healthcare Health Ab | Nicotine formulations and use thereof |
| US20050123502A1 (en) | 2003-10-07 | 2005-06-09 | Chan Shing Y. | Nicotine containing oral compositions |
| WO2005053691A2 (en) | 2003-12-02 | 2005-06-16 | Fertin Pharma A/S | Nicotine delivery product and method for producing it |
| WO2006058536A1 (en) | 2004-11-30 | 2006-06-08 | Fertin Pharma A/S | Method of providing fast relief to a user of a nicotine chewing gum |
| WO2006100075A2 (en) | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US8323683B2 (en) | 2005-05-18 | 2012-12-04 | Mcneil-Ppc, Inc. | Flavoring of drug-containing chewing gums |
| WO2006128468A1 (en) | 2005-06-01 | 2006-12-07 | Fertin Pharma A/S | A method of manufacturing a nicotine delivery product |
| AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| EP1998755A2 (en) * | 2006-03-16 | 2008-12-10 | NicoNovum AB | Chewing gum compositions providing rapid release of nicotine |
| US20070269492A1 (en) | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
| US20070269386A1 (en) | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
| US8642016B2 (en) | 2006-07-21 | 2014-02-04 | Jsrnti, Llc | Medicinal delivery system, and related methods |
| CN101516426A (zh) | 2006-09-27 | 2009-08-26 | 尼克诺姆股份公司 | 定向用途 |
| BRPI0719428A2 (pt) * | 2006-12-01 | 2014-02-25 | Cima Labs Inc | Forma de dosagem transmucosal oral sólida, método para tratar dependência de nicotina em um receptor que deseja tal tratamento, sistema de distribuição de nicotina transmucosal oral, e, método de substituíção de nicotina. |
| US20080286340A1 (en) | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered nicotine containing products |
| US20080286341A1 (en) | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered coated nicotine containing products |
| US20080292683A1 (en) | 2007-05-24 | 2008-11-27 | Monosolrx, Llc. | Film shreds and delivery system incorporating same |
| US20090004248A1 (en) | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
| US20090081291A1 (en) | 2007-09-26 | 2009-03-26 | Gin Jerry B | Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User |
| US8039620B2 (en) | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
| US20100018539A1 (en) | 2008-07-28 | 2010-01-28 | Paul Andrew Brinkley | Smokeless tobacco products and processes |
-
2010
- 2010-04-28 US US12/769,335 patent/US20110268809A1/en not_active Abandoned
-
2011
- 2011-04-26 WO PCT/US2011/033928 patent/WO2011139684A2/en not_active Ceased
- 2011-04-26 EP EP11717898A patent/EP2563330A2/en not_active Withdrawn
- 2011-04-26 JP JP2013508152A patent/JP5981416B2/ja active Active
- 2011-04-26 CN CN2011800285443A patent/CN102933199A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1039530A (zh) * | 1987-02-10 | 1990-02-14 | R.J.雷诺兹烟草公司 | 香烟 |
| CN1738621A (zh) * | 2002-12-20 | 2006-02-22 | 尼科诺瓦姆股份公司 | 物理和化学稳定的含尼古丁的颗粒物质 |
| WO2006004646A1 (en) * | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
| US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
| CN101528199A (zh) * | 2006-03-16 | 2009-09-09 | 尼科诺瓦姆股份公司 | 改良的鼻烟组合物 |
| CN101563071A (zh) * | 2006-12-01 | 2009-10-21 | 赛福伦公司 | 尼古丁经口粘膜剂型 |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105263345A (zh) * | 2013-05-06 | 2016-01-20 | 派克斯实验公司 | 用于气溶胶装置的烟碱盐调配物及其方法 |
| US12156533B2 (en) | 2013-05-06 | 2024-12-03 | Juul Labs, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
| US11510433B2 (en) | 2013-12-05 | 2022-11-29 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
| US11744277B2 (en) | 2013-12-05 | 2023-09-05 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
| US12167744B2 (en) | 2013-12-05 | 2024-12-17 | Juul Labs, Inc. | Nicotine liquid formulations for aerosol devices and methods thereof |
| CN108495563A (zh) * | 2015-11-25 | 2018-09-04 | R.J.雷诺兹烟草公司 | 烟碱盐、共晶体和盐共晶体配合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110268809A1 (en) | 2011-11-03 |
| JP2013527167A (ja) | 2013-06-27 |
| WO2011139684A3 (en) | 2012-03-08 |
| EP2563330A2 (en) | 2013-03-06 |
| WO2011139684A2 (en) | 2011-11-10 |
| JP5981416B2 (ja) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102933199A (zh) | 含有烟碱的药物组合物 | |
| US9937168B2 (en) | Nicotine-containing pharmaceutical compositions | |
| EP3744313B1 (en) | Excipients for nicotine-containing therapeutic compositions | |
| CN101687043B (zh) | 用氨基酸缓冲的带包衣的口服尼古丁制剂 | |
| KR101946774B1 (ko) | 설하 필름 | |
| JP2023061939A (ja) | 多層状ニコチン含有医薬組成物 | |
| JP2009529561A (ja) | ニコチンの速やかな放出をもたらす安定なロゼンジ組成物 | |
| CA2702614A1 (en) | Composition for administering an active ingredient and method for making and using the same | |
| JP2018529401A (ja) | 治療用組成物および構成 | |
| US20170165252A1 (en) | Protein-enriched therapeutic composition | |
| CN101677994A (zh) | 褪黑激素片剂及制备和使用的方法 | |
| CN102036657A (zh) | 含有烟碱和缓冲剂的可压片的口香糖 | |
| CN101795710A (zh) | 用氨基酸缓冲的口服尼古丁制剂 | |
| AU2007298814A1 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| JP2013144717A (ja) | ピタバスタチン又はその塩の苦味抑制方法 | |
| CN101460144A (zh) | AchE-NMDA组合物干胶片 | |
| JP2007509031A (ja) | ガランタミンの口腔用製剤およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130213 |